Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
B.L. Riggs, A.M. Parfitt.
Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelling.
J Bone Miner Res, 20 (2005), pp. 177-184
[2.]
A. Cranney, G. Guyat, L. Griffith, G. Wells, P. Tugwell, C. Rosen, The Osteoporosis Methodology group, and the Osteoporosis Research Advisory Group.
Summary of meta-analyses of therapies for postmenopausal osteoporosis.
Endocrine Reviews, 23 (2002), pp. 570-578
[3.]
P.J. Meunier, C. Roux, E. Seeman, S. Ortolani, J.E. Badurski, T.D. Spector, et al.
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
N Engl J Med, 350 (2004), pp. 459-468
[4.]
R.M. Neer, C.D. Arnaud, J.R. Zancheta, R. Prince, G.A. Gaich, J.Y. Reginster, et al.
Effect of parathyroid hormone [1-34] on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med, 344 (2001), pp. 1434-1441
[5.]
J.P. Brown, M. Fortier, The Osteoporosis Guidelines Committee.
Canadian Consensus Conference on Osteoporosis, 2006 Update.
J Obstet Gynaecol Can, 28 (2006), pp. S95-S112
[6.]
R.R. Recker, R. Gallagher, P.E. MacCosbe.
Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.
Mayo Clin Proc, 80 (2005), pp. 856-861
[7.]
C.H. Chesnut III, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hoiseth, et al.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res, 19 (2004), pp. 1241-1249
[8.]
I.R. Reid, J.P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, et al.
Intravenous zoledronic acid in opostmenopausal women with low bone mineral density.
N Engl J Med, 346 (2002), pp. 653-661
[9.]
European Medicines Agency. Preotact. European Public Assessment Report. Disponible en: http://www.emea.eu.int/humandocs/Humans/EPAR/preotact/preotact.htm
[10.]
L.C. Hofbauer, M. Schoppet.
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
JAMA, 292 (2004), pp. 490-495
[11.]
M.R. McClung, E.M. Lewiecki, S.B. Cohen, M.A. Bolognese, G.C. Woodson, A.H. Moffett, et al.
Denosumab in postmenopausal women with low bone mineral density.
N Engl J Med, 354 (2006), pp. 821-831
[12.]
N.B. Watts, T. Harris, H.K. Genant.
Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty.
Osteoporos Int, 12 (2001), pp. 429-437
[13.]
Writing Group for the Women's Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
[14.]
H.G. Bone, D. Hosking, J.P. Devogelaer, J.R. Tucci, R.D. Emkey, R.P. Tonino, et al.
Ten years’ experience with alendronate for osteoporosis in postmenopausal women.
N Engl J Med, 350 (2004), pp. 1189-1199
[15.]
C.H. Chesnut III, C.J. Rosen, For the Bone Quality Discussion Group.
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fractures.
J Bone Miner Res, 16 (2001), pp. 2163-2172
Copyright © 2006. Elsevier España S.L. Barcelona
